Filing Details

Accession Number:
0001062993-21-000289
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-12 16:10:49
Reporting Period:
2021-01-08
Accepted Time:
2021-01-12 16:10:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1616212 Trillium Therapeutics Inc. TRIL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1838044 Penka Petrova C/O Trillium Therapeutics Inc.
2488 Dunwin Drive
Mississauga A6 L5L 1J9
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-01-08 2,604 $3.33 2,604 No 4 M Direct
Common Shares Disposition 2021-01-08 2,604 $15.50 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2021-01-08 2,604 $0.00 2,604 $3.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
57,292 2028-11-08 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.